convalescent plasma

July 7, 2022

Convalescent plasma doesn’t help severely ill COVID patients: study

A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover

By Nancy Humphrey
February 5, 2021

Convalescent plasma improved survival in COVID-19 patients with blood cancers

Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

By Tom Wilemon
U.S. Health and Human Services Secretary Alex Azar visited VUMC Tuesday, Sept. 15, to learn more about the Medical Center’s ongoing Moderna COVID-19 vaccine trial and the convalescent plasma trial. Both studies are funded through the National Institutes of Health’s Operation Warp Speed. In the photo above, Azar and VUMC’s Jennifer Pietenpol, PhD, speak with reporters during a press conference following Azar’s visit.
September 17, 2020

HHS Secretary Azar visits VUMC

U.S. Health and Human Services Secretary Alex Azar visited VUMC Tuesday, Sept. 15, to learn more about the Medical Center’s ongoing Moderna COVID-19 vaccine trial and the convalescent plasma trial.

By VUMC News and Communications
August 21, 2020

VUMC awarded $34 million to lead nationwide convalescent plasma study

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19.

By Bill Snyder